Nabors L Burt, Surboeck Birgit, Grisold Wolfgang
Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Neurology, Kaiser-Franz-Josef Hospital, Vienna, Austria.
Handb Clin Neurol. 2016;134:235-50. doi: 10.1016/B978-0-12-802997-8.00014-1.
The pharmacotherapy management of cancers of the nervous system has significant overlap with systemic solid cancers that may utilize similar drugs or agents. There is however a unique aspect related to central nervous system (CNS) cancers where therapies directed against a malignant process may have enhanced toxicities or toxicities unique to the CNS. In addition, many agents used to treat CNS malignancies have unique CNS toxicities that may require a specific intervention. This chapter attempts to review conventional and biologic therapies utilized for CNS malignancies and characterize expected and, if known, unique toxicities.
神经系统癌症的药物治疗管理与可能使用相似药物或制剂的全身性实体癌有显著重叠。然而，中枢神经系统（CNS）癌症存在一个独特之处，即针对恶性病变的疗法可能具有增强的毒性或中枢神经系统特有的毒性。此外，许多用于治疗中枢神经系统恶性肿瘤的药物具有独特的中枢神经系统毒性，可能需要特定的干预措施。本章试图回顾用于中枢神经系统恶性肿瘤的传统疗法和生物疗法，并描述预期的毒性以及（若已知）独特的毒性。
